Greenwich Lifesciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Snehal Patel, CEO and CFO, a Director and 10% owner of Greenwich LifeSciences, Inc., purchased 2,200 shares of common stock on July 28, 2026.
NASDAQ
Snehal Patel, CEO and CFO, a Director and 10% owner of Greenwich LifeSciences, Inc., purchased 1,500 shares of common stock on July 27, 2026 for $13.62 per share.
NASDAQ
Snehal Patel, CEO and CFO, a Director and 10% owner of Greenwich LifeSciences, Inc., purchased 3,600 shares of common stock on July 23, 2026.
NASDAQ
Greenwich LifeSciences CEO and CFO Snehal Patel purchased 1,800 shares of common stock, signaling insider confidence.
NASDAQ
Greenwich LifeSciences CEO and CFO Snehal Patel purchased 2,900 shares of common stock at $27.54 per share, increasing beneficial ownership to over 5.6 million shares.
NASDAQ
Greenwich LifeSciences' CEO and CFO, Snehal Patel, acquired 4,300 shares of common stock at $21.36 per share, increasing beneficial ownership to 5,599,402 shares.
NASDAQ
Form 4: GLSI CEO & CFO Buys Shares
Greenwich LifeSciences' CEO and CFO, Snehal Patel, purchased 2,900 shares of common stock at $21.73 per share.
NASDAQ
Greenwich LifeSciences' CEO and CFO, Snehal Patel, acquired 4,100 shares of common stock at $12.62 per share, increasing beneficial ownership to over 5.5 million shares.
NASDAQ
Form 4: GLSI CEO Buys 4,600 Shares
Greenwich LifeSciences CEO and CFO Snehal Patel purchased 4,600 shares of common stock at $8.37 per share.
NASDAQ
Greenwich LifeSciences CEO and CFO Snehal Patel acquired 100,000 stock options exercisable at $8.20 per share, signaling potential confidence in future growth.
NASDAQ
Greenwich LifeSciences, Inc. CEO and CFO, Snehal Patel, acquired 10,600 shares of common stock at $8.43 per share, increasing beneficial ownership to 5,583,502 shares.
NASDAQ
Form 4: GLSI CEO & CFO Buys 2,300 Shares
Greenwich LifeSciences CEO and CFO Snehal Patel purchased 2,300 shares of common stock at $9.26 per share.
NASDAQ
Snehal Patel, CEO and CFO of Greenwich LifeSciences, purchased 3,600 shares of common stock at $9.88 per share on April 25, 2025, increasing their direct holdings to 5,570,602 shares.
NASDAQ
Snehal Patel, CEO and CFO of Greenwich LifeSciences, reports the acquisition of 5,400 shares of common stock at $8.98 per share on April 17, 2025.
NASDAQ
Greenwich LifeSciences CEO Snehal Patel reports the acquisition of 3,600 shares of common stock at a price of $9.1 per share on April 7, 2025.
NASDAQ
CEO and CFO Snehal Patel of Greenwich LifeSciences, Inc. reports purchasing 5,500 shares of common stock at $8.73 per share on April 4, 2025.
NASDAQ
Snehal Patel, CEO and CFO of Greenwich LifeSciences, recently acquired 2,500 shares of the company's common stock at a price of $12.51 per share.
NASDAQ
Greenwich LifeSciences CEO and CFO, Snehal Patel, has increased their holdings in the company through open market purchases of common stock.
NASDAQ
Snehal Patel, CEO and CFO of Greenwich LifeSciences, purchased 3,400 shares of common stock at $12.95 per share on January 3, 2025.
NASDAQ
Greenwich LifeSciences CEO, Snehal Patel, purchased 2,000 shares of common stock at $11.97 per share on January 2, 2025.
NASDAQ
Greenwich LifeSciences CEO, Snehal Patel, purchased 2,400 shares of the company's common stock at $11.36 per share on December 31, 2024.
NASDAQ
Greenwich LifeSciences CEO, Snehal Patel, purchased 3,200 shares of the company's common stock at $11.12 per share on December 30, 2024.
NASDAQ
Frank Daugherty, Chief Medical Officer of Greenwich LifeSciences, was granted 104,890 stock options on December 24, 2024.
NASDAQ
Kenneth Hallock, a director at Greenwich LifeSciences, acquired 41,349 stock options on December 24, 2024.
NASDAQ
Director Eric Rothe of Greenwich LifeSciences, Inc. acquired 41,349 stock options on December 24, 2024, increasing his total holdings to 82,698.
NASDAQ
Snehal Patel, CEO and CFO of Greenwich LifeSciences, reported the acquisition of stock options, both directly and indirectly through his wife, on December 24, 2024.
NASDAQ
Jaye Thompson, VP of Clinical Regulatory Affairs at Greenwich LifeSciences, acquired 149,818 stock options on December 24, 2024.
NASDAQ
David McWilliams, a director at Greenwich LifeSciences, acquired 61,984 stock options on December 24, 2024.
NASDAQ
Jaye Thompson, VP of Clinical Regulatory Affairs at Greenwich LifeSciences, acquired 1,000 shares of common stock at $12.91 per share on November 21, 2024.
NASDAQ
Snehal Patel, CEO and CFO of Greenwich LifeSciences, recently purchased 1,500 shares of common stock at $14.63 per share.